7 minute read
Mar. 31, 2024

Patent Highlights: Synthetic Lethal MTA-Cooperative PRMT5 Inhibitors, TYK2 Degraders, Mutant p53 Reactivators, and More

February 2024 saw numerous notable patent disclosures aimed at a variety of therapeutic targets across different disease areas. The Drug Hunter team has compiled a searchable table that includes more than 200 patents of relevance to the drug discovery industry. Accompanying the table are detailed notes, as well as standout features from some of our top picks, including MTA-cooperative PRMT5 inhibitors, heterobifunctional TYK2 degraders, strategies for engaging and reactivating mutant p53, and more.



Other articles you may be interested in